Would you consider PMRT for non-mass like enhancement >5cm on breast MRI that resolves with NAC and has a pCR?

For clinical T3No with pCR, limited data suggest low risk of LRR and I usually avoid PMRT unless triple negative or multiple adverse factors on pretreatment pathology and imaging.

If the non-mass like enhancement is considered in your clinical staging as cT3, we can look to the old NSABP experience on rates and patterns of LRR in patients treated with NAC but without PMRT, i.e., NSABP B-18 and B-27. They examined the 10-year cumulative incidence of LRR in patients with >5cm t...